{"id":42370,"date":"2025-08-09T11:35:05","date_gmt":"2025-08-09T11:35:05","guid":{"rendered":"https:\/\/quickassetsmarket.com\/index.php\/2025\/08\/09\/natera-shares-surge-17-after-strong-q2-results-and-upgraded-guidance\/"},"modified":"2025-08-09T11:35:05","modified_gmt":"2025-08-09T11:35:05","slug":"natera-shares-surge-17-after-strong-q2-results-and-upgraded-guidance","status":"publish","type":"post","link":"https:\/\/quickassetsmarket.com\/index.php\/2025\/08\/09\/natera-shares-surge-17-after-strong-q2-results-and-upgraded-guidance\/","title":{"rendered":"Natera shares surge 17% after strong Q2 results and upgraded guidance"},"content":{"rendered":"
<\/div>\n

Shares of genetic testing company Natera (NASDAQ:NTRA) jumped sharply in morning trading, rising as much as 17% after the company reported better-than-expected second-quarter 2025 financial results and raised its full-year revenue forecast. <\/p>\n

The stock later closed at 7.7% in the green. <\/p>\n

Wall Street welcomed the revenue beat and the upgraded guidance, despite a wider-than-expected loss per share.<\/p>\n

Revenue beats estimates, sales jump 32%<\/h2>\n

Natera reported Q2 revenue of $546.6 million, a 32.2% increase from the same period last year, beating Wall Street expectations. <\/p>\n

This strong performance was driven by a 12.7% increase in the number of tests processed, reflecting sustained demand for the company\u2019s genetic testing offerings.<\/p>\n

Founded in 2003 and headquartered in Austin, Texas, Natera specializes in prenatal screening, cancer detection, and organ transplant monitoring using proprietary DNA analysis technology. <\/p>\n

CEO Steve Chapman attributed the quarter\u2019s performance to \u201crecord Signatera growth\u201d and ongoing strength in the women\u2019s health and organ health product lines.<\/p>\n

Despite the strong revenue numbers, Natera reported a GAAP loss per share of $0.74, which was worse than the expected loss of $0.62. <\/p>\n

The company remains unprofitable but has been demonstrating consistent top-line growth.<\/p>\n

Guidance raised as company signals confidence<\/h2>\n

Alongside its quarterly results, Natera raised its full-year 2025 revenue guidance to a midpoint of $2.06 billion, up $80 million from its previous projection and 4% above Wall Street\u2019s expectations. <\/p>\n

The new outlook suggests management is confident in maintaining the company\u2019s growth trajectory for the rest of the year.<\/p>\n

Prior to the Q2 announcement, Natera shares had been under pressure and were up only 2% year-to-date. <\/p>\n

The results have now helped boost investor sentiment, pushing the stock higher and potentially shifting analyst expectations for the remainder of the year.<\/p>\n

Analyst upgrades and market outlook<\/h2>\n

Natera\u2019s stock holds a consensus Strong Buy rating from 11 Wall Street analysts, all of whom have issued Buy recommendations in the past three months. <\/p>\n

The average price target before the Q2 report was $201.56, implying a 43.85% upside from recent levels.<\/p>\n

Following the earnings release, RBC Capital raised its price target on Natera to $255 from $251 while maintaining its Outperform rating. <\/p>\n

The firm described Q2 as \u201canother noteworthy quarter\u201d for the company, with particular strength in Signatera testing volumes and average selling prices contributing to the revenue beat. <\/p>\n

RBC also pointed to Natera\u2019s strong balance sheet, including a current ratio of 3.87 and a gross profit margin of 61.79%.<\/p>\n

RBC noted that Natera remains its \u201cfavorite liquid biopsy idea,\u201d citing the scarcity of high-growth opportunities in the healthcare sector. <\/p>\n

The firm added that the company has multiple \u201cshots on goal\u201d across short, medium, and long-term horizons.<\/p>\n

While Natera\u2019s shares may be trading above certain fair value estimates, the company\u2019s robust growth, upgraded guidance, and analyst support suggest it will remain a closely watched healthcare stock in the coming quarters.<\/p>\n<\/p>\n

The post Natera shares surge 17% after strong Q2 results and upgraded guidance<\/a> appeared first on Invezz<\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Shares of genetic testing company Natera (NASDAQ:NTRA) jumped sharply in morning trading, rising as much as 17% after the company reported better-than-expected second-quarter 2025 financial results and raised its full-year revenue forecast. The stock later closed at 7.7% in the green. Wall Street welcomed the revenue beat and the upgraded guidance, despite a wider-than-expected loss <\/p>\n","protected":false},"author":1,"featured_media":42371,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":{"0":"post-42370","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-investing"},"_links":{"self":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts\/42370","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/comments?post=42370"}],"version-history":[{"count":0,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts\/42370\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/media\/42371"}],"wp:attachment":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/media?parent=42370"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/categories?post=42370"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/tags?post=42370"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}